MedTrace Logo

Efficacy and Tolerability of Riluzole in Treatment Resistant Depression

NCT01204918 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2020-03-06

Study results available
· View outcomes & findings →

Summary

This study aims to examine the antidepressant efficacy of riluzole, employing a randomized, double-blind, placebo-controlled, adjunctive trial in treatment-resistant major depressive disorder (TRD).

Conditions

Interventions

DRUG

Riluzole

Riluzole 100mg PO

DRUG

placebo

placebo

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Gerard Sanacora, MD PhD · Yale University

  • Maurizio Fava, MD · Massachusettes General Hospital

  • Sanjay Matthew, MD · Baylor College of Medicine

  • Carlos Zarate, MD · National Institute of Mental Health (NIMH)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2015-05-31
Completion
2015-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01204918 on ClinicalTrials.gov